Drug Profile
Research programme: inflammation therapeutics - Cellzome/GlaxoSmithKline
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Cellzome; GlaxoSmithKline
- Developer Cellzome; GSK
- Class Small molecules
- Mechanism of Action Immunogenetic modulators; Inflammation mediator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Inflammation in England (PO)
- 16 Jul 2016 No recent reports of development identified for research development in Inflammation in Germany (PO)
- 21 May 2012 Cellzome has been acquired and merged into GlaxoSmithKline